Provided by Tiger Trade Technology Pte. Ltd.

Insulet

225.50
-1.5800-0.70%
Post-market: 225.500.00000.00%18:02 EDT
Volume:546.95K
Turnover:123.31M
Market Cap:15.86B
PE:64.82
High:227.98
Open:225.34
Low:221.28
Close:227.08
52wk High:354.88
52wk Low:216.49
Shares:70.35M
Float Shares:70.08M
Volume Ratio:0.64
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.48
EPS(LYR):3.48
ROE:18.12%
ROA:9.43%
PB:10.47
PE(LYR):64.82

Loading ...

Barclays Sticks to Their Hold Rating for Insulet (PODD)

TIPRANKS
·
Nov 05, 2025

Insulet Corporation Files Initial Statement of Beneficial Ownership for Director Robert Luther Huffines

Reuters
·
Nov 04, 2025

Insulet Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Nov 04, 2025

Insulet Corp. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Oct 30, 2025

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 28, 2025

Insulet’s Omnipod 5 Study: A Real-World Evaluation of Diabetes Management

TIPRANKS
·
Oct 28, 2025

1 Safe-and-Steady Stock to Own for Decades and 2 We Brush Off

stock_story_highlight
·
Oct 27, 2025

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Oct 24, 2025

Insulet (PODD) Valuation in Focus After Board Addition and Upbeat Analyst Upgrades

Simply Wall St.
·
Oct 24, 2025

Insulet Appoints Robbie Huffines as New Director

TIPRANKS
·
Oct 23, 2025

Insulet Appoints Robert L. Huffines to Board of Directors

Reuters
·
Oct 23, 2025

Insulet Announces Appointment of Robert L. Huffines to Its Board of Directors

THOMSON REUTERS
·
Oct 23, 2025

Insulet Corp : Stifel Resumes Coverage With Buy Rating; Price Target $370

THOMSON REUTERS
·
Oct 21, 2025

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 21, 2025

Leerink Partners Keeps Their Buy Rating on Insulet (PODD)

TIPRANKS
·
Oct 16, 2025

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 15, 2025

Will Insulet’s (PODD) Innovation Roadmap Reinforce Its Competitive Edge in Diabetes Technology?

Simply Wall St.
·
Oct 15, 2025

Leerink Partners Adjusts Price Target on Insulet to $355 From $339, Maintains Outperform Rating

MT Newswires Live
·
Oct 14, 2025

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

GlobeNewswire
·
Oct 13, 2025

Insulet price target raised to $365 from $350 at RBC Capital

TIPRANKS
·
Oct 10, 2025